Pharma Tech

BMS secures FDA accelerated approval for Zenbexus in multiple myeloma

Aug 14, 2026, 9:27 AM

Read Full Article → BMS secures FDA accelerated approval for Zenbexus in multiple myeloma

Translate article text

Choose a language and wait for the translated text.

The FDA has granted accelerated approval to BMS' Zenbexus, along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma.